Valerio Bianchi

Associate, Milan

Biography

Overview

Valerio Bianchi is an associate in the Milan office and practices in the areas of private M&A, Private Equity and Corporate.

Valerio advises Italian and international private equity sponsors, industrial clients and investment banks on a range of transactions including acquisitions, joint ventures, equity investments and co-investments and disposals in a wide range of sectors, including oil & gas, pharmaceutical and healthcare, infrastructure and transport, retail and consumer products and services, technology.

Prior to joining White & Case Valerio practiced in a major international law firm in Milan in the Corporate and M&A department.

Bars and Courts
Italian Bar
Education
Law Degree
Bocconi University

Milan, Italy

Languages
Italian
English

Experience

Adler Pelzer Holding GmbH, a worldwide leader in the design, engineering and manufacturing of acoustic and thermal components and systems for the automotive sector, in connection with a €68 million term facility agreement.

Huvepharma EOOD in connection with the sale of its subsidiary, Huvepharma Italia S.r.l., to Olon S.p.A., a prominent player in the pharmaceutical industry.

PAI Partners in connection with the acquisition of a majority stake of Beautynova, a global leader in the professional haircare products sector, from Bluegem. PAI Partners is a pre-eminent private-equity firm investing in market-leading companies across the globe.

I.M.A. Industria Macchine Automatiche S.p.A. and its controlling shareholders in connection with an investment from BDT & MSD Partners. BDT & MSD Partners acquires its stake from international private equity fund BC Partners. The Vacchi family remains the majority owner of the IMA holding company.

Eni S.p.A. in connection with its agreement to acquire Neptune Energy Group Limited, a leading independent exploration and production company with a portfolio of gas-oriented assets and operations in Western Europe, North Africa, Indonesia and Australia, for a total value of US$4.9 billion.

Accelleron Industries AG, leading developer and producer of turbochargers, in connection with its €103 million acquisition of Officine Meccaniche Torino S.p.A., a leading manufacturer of fuel injection systems for marine engines.

The managers and minority shareholders of the GeneraLife Group, a paneuropean KKR portfolio group active in the healthcare and human fertility business, in connection with its merger with IVI-RMA Group, a medical institution dedicated to assisted reproduction.

The Seller in connection with the sale of the entire share capital in Valeas S.p.A., a Milan based pharmaceutical company active in the Italian market.

Mediobanca and Intesa Sanpaolo, as joint global coordinators and joint bookrunners, in connection with the Regulation S initial public offering of Technoprobe S.p.A.'s ordinary shares on Euronext Growth Milan, in which 20.8% of the total share capital of the company's shares were offered, for a total value of €713 million and a market capitalization of approximately €3.426 billion.

Verlinvest S.A., a privately-owned investment group headquartered in Brussels, in connection with its US$100 million investment in Everli, Europe's leading marketplace for online grocery shopping.

Gruppo Investimenti Portuali S.p.A. (a portfolio company of the private equity funds Infracapital and InfraVia) in connection with its merger with PSA Italy, the Italian subsidiary of the Port Authority of Singapore, which has created the largest terminal container operation managed by foreign investors in the Italian market.

BC Partners in connection with the M&A, financing, capital markets and regulatory aspects of BC Partners' acquisition of an up to approximately 45 percent stake in SOFIMA, the holding company that controls IMA S.p.A., for a total value of almost €2.1 billion.

Italian pharma and consumer healthcare group Angelini in connection with its worldwide acquisition, outside North America, of ThermaCare from GlaxoSmithKline (GSK). The acquisition is a key transaction in relation to the creation of the GSK/Pfizer JV for Consumer Health.